Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin on Recurrence and Survival in Colon Cancer Patients
2022-502324-48-00Phase 3Authorised
- Sponsor
- Leiden University Medical Center
- Start
- Feb 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in colon cancer and colon adenocarcinoma comparing Acetylsalicylic acid with Placebo (2 arms). Primary endpoint: 5-year overall survival. Planned start Feb 2023; status: authorised.
02
Drugs
aspirin
03
Conditions
colon cancercolon adenocarcinoma
Beyond the preview
Go deeper on 2022-502324-48-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502324-48-00.